

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-69. (Cancelled)

70-95. (Cancelled)

96. (Currently Amended) A ~~DNA sequence~~ polynucleotide encoding a heavy chain or a variable heavy chain region of an antibody ~~or a fragment thereof~~ that binds human IL-13, wherein said antibody ~~binds to an epitope comprising the sequence~~ ESLINVSG (SEQ ID NO: 18) or YCAALESLINVS (SEQ ID NO: 19) comprises antigen-binding regions derived from an anti-IL-13 antibody comprising the amino acid sequence of an antibody produced by a hybridoma designated with American Type Culture Collection ("ATCC") accession number PTA-5657.

97. (Currently Amended) A ~~DNA sequence~~ polynucleotide encoding a light chain or a variable light chain region of an antibody ~~or a fragment thereof~~ that binds human IL-13, wherein said antibody ~~binds to an epitope comprising the sequence~~ ESLINVSG (SEQ ID NO: 18) or YCAALESLINVS (SEQ ID NO: 19) comprises antigen-binding regions derived from an anti-IL-13 antibody comprising the amino acid sequence of an antibody produced by a hybridoma designated with ATCC accession number PTA-5657.

98. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 96, ~~which encodes a heavy chain or a fragment thereof comprising~~ wherein said antibody that binds human IL-13 comprises (i) complementarity determining regions CDRH1, CDRH2 and CDRH3 with having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and (ii) complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

99. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 97, ~~which encodes a light chain or a fragment thereof comprising~~ wherein said antibody that binds human IL-13 comprises (ii) complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and (ii) complementarity determining regions CDRL1, CDRL2 and CDRL3 with having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

100. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 96, ~~which encodes a heavy chain or a fragment thereof comprising~~ wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143.

101. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 97, ~~which encodes a light chain or a fragment thereof comprising~~ wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 142.

102. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 96 ~~which encodes a heavy chain or a fragment thereof comprising~~, wherein said antibody that binds human IL-13 comprises:

- (1) a CDRH1 having the amino acid sequence of SEQ ID NO: 117, 118, 119, 120, 121 or 122;
- (2) a CDRH2 having the amino acid sequence of SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134; and
- (3) a CDRH3 having the amino acid sequence of SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141.

103. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 97 ~~which encodes a light chain or a fragment thereof comprising~~, wherein said antibody that binds human IL-13 comprises:

(1) a CDRL1 having the amino acid sequence of SEQ ID NO: 99, 100, 101, 102, or 103;

(2) a CDRL2 having the amino acid sequence of SEQ ID NO: 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and

(3) a CDRL3 having the amino acid sequence of SEQ ID NO: 115 or 116.

104. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 96 ~~which encodes a heavy chain or a fragment thereof comprising, wherein said antibody that binds human IL-13 comprises~~ the amino acid sequence of SEQ ID NO: 4, 143, 145, 146, 147, 148 or 149.

105. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 97 ~~which encodes a light chain or a fragment thereof comprising, wherein said antibody that binds human IL-13 comprises~~ the amino acid sequence of SEQ ID NO: 3, 142, 144 or 150.

106. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 96 or 98, ~~which encodes a heavy chain or a fragment thereof of wherein said antibody that binds human IL-13 is selected from the group consisting of: a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, an antibody fragment, a single chain antibody, a Fab fragment, and a F(ab') fragment, or a single domain antibody.~~

107. (Currently Amended) The ~~DNA sequence~~ polynucleotide of claim 97 or 99, ~~which encodes a light chain or a fragment thereof of wherein said antibody that binds human IL-13 is selected from the group consisting of: a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, an antibody fragment, a single chain antibody, a Fab fragment, and a F(ab') fragment, or a single domain antibody.~~

108. (Cancelled) ~~A vector comprising the DNA sequence of claim 96 or 99.~~

109. (Cancelled) ~~A host cell comprising the vector of claim 108.~~

110. (New) The polynucleotide of claim 104, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 4.

111. (New) The polynucleotide of claim 105, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 3.
112. (New) The polynucleotide of claim 106, wherein the antibody is a multispecific antibody that is a bispecific antibody.
113. (New) The polynucleotide of claim 107, wherein the antibody is a multispecific antibody that is a bispecific antibody.
114. (New) The polynucleotide of claim 106, wherein the antibody is a humanized antibody.
115. (New) The polynucleotide of claim 107, wherein the antibody is a humanized antibody.
116. (New) A polynucleotide encoding a heavy chain or a variable heavy chain region of an antibody that binds human IL-13, wherein said antibody is a humanized antibody of an antibody produced by a hybridoma designated with ATCC accession number PTA-5657.
117. (New) A polynucleotide encoding a light chain or a variable light chain region of an antibody that binds human IL-13, wherein said antibody is a humanized antibody of an antibody produced by a hybridoma designated with ATCC accession number PTA-5657.
118. (New) A polynucleotide encoding a heavy chain or a variable heavy chain region of an antibody that binds human IL-13, wherein said antibody comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.
119. (New) A polynucleotide encoding a light chain or a variable light chain region of an antibody that binds human IL-13, wherein said antibody comprises a variable heavy chain

region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

120. (New) The polynucleotide of claim 116, wherein said antibody that binds human IL-13 comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

121. (New) The polynucleotide of claim 117, wherein said antibody that binds human IL-13 comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

122. (New) The polynucleotide of claim 116, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

123. (New) The polynucleotide of claim 117, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

124. (New) The polynucleotide of claim 118, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

125. (New) The polynucleotide of claim 119, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.
126. (New) The polynucleotide of claim 116, 117, 120, or 121, wherein said antibody that binds human IL-13 is selected from the group consisting of: a monovalent antibody, a multispecific antibody, a single chain antibody, a Fab fragment, and a F(ab') fragment.
127. (New) The polynucleotide of claim 126, wherein said antibody that binds human IL-13 is a multispecific antibody that is a bispecific antibody.
128. (New) The polynucleotide of claim 116, 117, 120, or 121, wherein said antibody is a monoclonal antibody.
129. (New) The polynucleotide of claim 118, or 119, wherein said antibody that binds human IL-13 is selected from the group consisting of: a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a Fab fragment, and a F(ab') fragment.
130. (New) The polynucleotide of claim 129, wherein said antibody that binds human IL-13 is a multispecific antibody that is a bispecific antibody.
131. (New) The polynucleotide of claim 118 or 119, wherein said antibody is a monoclonal antibody.
132. (New) The polynucleotide of claim 116, 117, 120, or 121, wherein the antibody is an IgG antibody.
133. (New) The polynucleotide of claim 118 or 119, wherein the antibody is an IgG antibody.
134. (New) The polynucleotide of claim 132, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
135. (New) The polynucleotide of claim 133, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

136. (New) The polynucleotide of claim 96, 97, 98, or 99, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
137. (New) The polynucleotide of claim 136, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
138. (New) A vector comprising one or more of the polynucleotide of claim 116, 117, 18, or 119.
139. (New) The vector of claim 138, wherein said vector comprises a polynucleotide encoding (i) a heavy chain or a variable heavy chain region, and (ii) a light chain or a variable light chain region, of the antibody that binds human IL-13.
140. (New) A host cell comprising one or more vectors of claim 138.
141. (New) A host cell comprising a vector of claim 139.
142. (New) The host cell of claim 140, wherein the host cell is a mammalian cell.
143. (New) The host cell of claim 141, wherein the host cell is a mammalian cell.
144. (New) The host cell of claim 142, wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.
145. (New) The host cell of claim 143, wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.
146. (New) The host cell of claim 140, wherein the host cell is a bacteria.
147. (New) The host cell of claim 141, wherein the host cell is a bacteria.
148. (New) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 140.
149. (New) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 141.
150. (New) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 142.

151. (New) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 143.

152. (New) The method claim 148, further comprising the step of obtaining the antibody expressed by the host cell.

153. (New) The method claim 149, further comprising the step of obtaining the antibody expressed by the host cell.

154. (New) The method claim 150, further comprising the step of obtaining the antibody expressed by the host cell.

155. (New) The method claim 151, further comprising the step of obtaining the antibody expressed by the host cell.